Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Weighted Avg Shares · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 81.84M shares rose 165.1% year over year, ahead of the +120.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 35.9% from the prior quarter. Over 3 fiscal years it compounded at +48.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +165.1% holds above the trailing-twelve-month pace of +120.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
81.84M+35.9% QoQ
Last fiscal yearSep 2025
34.8M+87.6% YoY
LTMMar 2026
53.45M+120.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+165.1%——
1 year+87.6%——
3-year CAGR+48.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
34.8M USD
Year-over-year change
+87.6%
4-year CAGR
+46.1%

Weighted Avg Shares vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 weighted avg shares of 53.45M shares is the 3rd highest of the 9 companies compared; the peer median is 28.65M shares.
  • Its year-over-year change of +120.6% is the highest of 9, against a peer median of +28.9%.
  • Over three fiscal years its annual growth of +48.6% compares with a peer median of +11.3%.
OTLK Competitors Peer median
Weighted Avg Shares for OTLK and competitors
Company Period LTM YoY 3-year CAGR
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
EQEquillium, Inc.LTM Mar 202664.9M +83.3%+39.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
HOWLWerewolf Therapeutics, Inc.LTM Jun 202647.17M +6.0%+16.8%
OSTXOS Therapies IncorporatedLTM Mar 202631.25M -31.1%+8.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202626.06M +115.3%-31.2%
COEPCoeptis Therapeutics, Inc.LTM Mar 20264.68M -77.3%-33.3%
CUECue Biopharma, Inc.LTM Mar 20263.74M +79.5%+38.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026827.01K +51.8%+7.8%
Peer median (excluding OTLK) 28.65M+28.9%+11.3%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.